LanPure / Alta Resource Technologies
LLNL’s Lanmodulin-Based Rare Earth Purification (LanPure) won FLC’s 2026 Excellence in Tech Transfer Award for its commercialization with Alta Resource Technologies, which exclusively licensed LanPure to recover valuable minerals from feedstocks historically too complex to process economically, such as mine tailings and electronic waste.
LanPure, developed in partnership with Pennsylvania State University, can selectively extract and separate rare-earth elements (REEs) essential for many electronic, energy and advanced defense technologies — enabling a resilient domestic supply chain for REEs and other critical minerals from diverse sources.
Winners: Yash Vaishnav, Business Development Executive, and colleague Samantha Madru in LLNL’s IPO. LLNL Group Leader for Synthetic Biology Dan Park and Deputy Division Leader Yongqin Jiao. Nathan Ratledge, co-founder and CEO of Alta Resource Technologies.
ATOM (Accelerating Therapeutics for Opportunities in Medicine)
The ATOM Consortium was founded in 2017 by LLNL, the Frederick National Laboratory for Cancer Research, the University of California, San Francisco (UCSF), and pharmaceutical company GSK (formerly GlaxoSmithKline). It is a multi-institutional computationally-driven initiative to develop a flexible platform for predictive antibody design and to increase pandemic readiness by accelerating discovery and development of biologics-based medical countermeasures.
Winners:
LLNL: Jim Brase, Jessica Mauvais, Stewart He, Kevin McLoughlin;
FNL: Eric Stahlberg, Justin Overhulse, Naomi Ohashi, Pinyi Lu, Sean Black;
UCSF: Amanda Paulson, Rebecca Lein
LLNL/EVOQ Therapeutics
LLNL's nanolipoprotein particles won the FLC 2024 Excellence in Technology Transfer Award.
This April, LLNL biologist Nicholas Fischer and Yash Vaishnav, a business development executive in the Lab’s Innovation and Partnerships Office (IPO) have garnered a Federal Laboratory Consortium (FLC) technology transfer award and honored during the FLC national meeting in Dallas, Texas.
The FLC award recognizes a LLNL biomedical technology called nanolipoprotein particles (NLPs) that can deliver vaccines and drugs inside the cells of the human body. The advance was licensed to Ann Arbor, Michigan-based EVOQ Therapeutics in 2017. EVOQ Therapeutics has been able to use the NLPs for lymph node-targeted delivery of specific antigens for autoimmune diseases such as Type 1 diabetes, rheumatoid arthritis, celiac disease, and others.
Winners:
Yash Vaishnav, Business Development Executive, LLNL Innovation and Partnerships Office
Nicholas Fischer, co-inventor and biologist, LLNL
David Giljohann, CEO, EVOQ Therapeutics
William Brinkerhoff, Co-founder and Board Chair (former CEO), EVOQ Therapeutics
Multifunctional, 3D-Printable Inks for Energy Products (Energy Inks)
LLNL's Energy Inks won the FLC 2023 Best in Far West Region Award. Energy Inks offer optimized functional properties to realize next-generation, high-performance 3D-printed devices for energy storage, catalysis, filtration, sensors, and more. By utilizing the design flexibility of direct ink writing, Energy Inks allow customizable battery and supercapacitor components to be 3D-printed faster and at lower cost while exhibiting higher performance than competitive technologies.
Winners:
LLNL: Marcus Worsley and Swetha Chandrasekaran; MilliporeSigma: Adam Raw and Monica Jung de Andrade | Collaborative support- UC Santa Cruz: Yat Li and Dun Lin; LLNL: Patrick Campbell, Maira Ceron-Hernandez, Alyssa Troksa, Josh Kuntz, Wyatt Du Frane and Genaro Mempin (LLNL Business Development Executive).
